We received a
Concern About Rasagiline Interactions
While it was appropriate for AR’s neighbor to limit tyramine intake and discontinue her selective serotonin reuptake inhibitor (SSRI) while using a nonselective monoamine oxidase inhibitor (MAOI), these recommendations do not necessarily apply to the use of selective MAO-B inhibitors. In fact, the FDA approved revised prescribing information for rasagiline in 2009 to reduce restrictions initially placed on this agent. Based on finding that rasagiline is a selective MAO-B inhibitor at recommended clinical doses, dietary restrictions related to normal dietary tyramine intake are not necessary. While the prescribing information does warn against use of rasagiline with SSRIs, concomitant SSRI use was allowed in clinical trials without any serotonin syndrome noted. In practice, MAO-B inhibitors are frequently used in combination with SSRIs in people with Parkinson’s disease (PD). In this case, AR was reassured about his continued use of rasagiline and escitalopram.
Regarding the use of rasagiline as a neuroprotective agent, evidence to date has failed to prove any effects on delayed PD disease progression. A systematic review published by the Movement Disorder Society reported insufficient evidence for the use of rasagiline to prevent disease progression, and the FDA likewise denied the addition of such an indication to the rasagiline prescribing information.
Jacqueline Groat, PharmD Student, Class of 2013
Joshua J. Neumiller, PharmD, CDE, CGP, FASCP
Department of Pharmacotherapy
College of Pharmacy
Washington State University
I would let the patient AR know that Azilect has a warning/precaution with all antidepressants, including the Lexapro he is taking, and it is best if he not take those two drugs concurrently. However, it is not a contraindication to take an antidepressant with Azilect. I would then refer him to his physician to make sure he/she is aware of this fact, and to consider holding the Azilect or waiting until AR has talked to his physician.
This elderly patient is taking three anti-Parkinson medications: Sinemet, Comtan, and rasagliline, all at the max or normal dose as adjunctive therapy to help him with the “wearing off” symptoms. He needs to be consulted for exacerbation of dyskinesias, which may require lowering the levodopa doses by 9% to 13%.
P. Pang, RPh
AR does not have to be worried about food interactions with his MAO-B inhibitor, since foods and beverages containing tyramine have not been shown to cause a "Cheese Effect" with rasagiline (or selegiline). An SSRI for depression may be OK, but observe for possibility of serotonin syndrome. Since AR is 71 years old and probably on Medicare, he might consider asking his physician (neurologist) to switch him to selegiline 5 mg once daily instead of rasagiline to try and keep him out of the “donut hole” with his prescription costs. Also, he should avoid alcohol due to diabetes mellitus and high-dose acetaminophen.
Stop Azilect and replace Sinemet with long-acting Sinemet. Azilect with Lexapro causes serotonin syndrome and with metformin may potentiate and prolong hypoglycemia response.
E. Shalaby, RPh
San Diego, California